Abstract
OPi (formerly Orphan Pharma International) is developing inolimomab, an anti-interleukin-2 receptor (CD25) monoclonal antibody for the potential treatment of acute graft versus host disease. As of April 2001, inolimomab was undergoing phase II/III clinical trials.
MeSH terms
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / therapeutic use*
-
Bone Marrow Transplantation
-
Clinical Trials as Topic
-
Graft vs Host Disease / drug therapy*
-
Heart Transplantation
-
Humans
-
Immunosuppressive Agents / therapeutic use*
Substances
-
Antibodies, Monoclonal
-
Immunosuppressive Agents
-
inolimomab